Pharmacokinetics and Safety of Fospropofol Disodium for Injection in Subjects with Hepatic Impairment Compared with Healthy Matched Controls: A Prospective Cohort Study Publication Pharmacokinetics and Safety of Fospropofol Disodium for Injection in Subjects with Hepatic Impairment Compared with Healthy Matched Controls: A Prospective Cohort Study Learn how faster fospropofol elimination but slower propofol clearance can help hepatic impairment, analysed using…CertaraOctober 17, 2025
Streamlining PK/PD reporting: A smarter approach to generating tables, figures and listings Blog Streamlining PK/PD reporting: A smarter approach to generating tables, figures and listings Discover how TFL Studio accelerates PK/PD reporting. Create audit-ready tables, figures, and listings faster with…CertaraOctober 16, 2025
Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results Publication Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…CertaraOctober 15, 2025
PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software Live Events PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software – Scarman, Coventry, UKCertaraOctober 14, 2025
Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain Publication Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain Find out how Phoenix NLME identifies pharmacogenetic drivers of flurbiprofen enantiomer clearance and CSF distribution…CertaraOctober 9, 2025
Alzheimer’s disease clinical trials and drug development: Building a robust clinical pharmacology & model-informed strategy Blog Alzheimer’s disease clinical trials and drug development: Building a robust clinical pharmacology & model-informed strategy Rajesh Krishna proposes using an integrated clinical pharmacology & model-informed strategy for Alzheimer's disease clinical…CertaraOctober 7, 2025
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions White Paper C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…CertaraOctober 3, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Case Study Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…CertaraOctober 2, 2025
Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects Publication Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects Explore how fed‑condition crossover study confirms bromocriptine mesylate bioequivalence and safety, analysed using Phoenix WinNonlin.CertaraSeptember 29, 2025
Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers Publication Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers Discover how oral solution and tablet formulations of SHR0302 show comparable bioavailability and safety in…CertaraSeptember 26, 2025